<?xml version="1.0" encoding="utf-8" ?>
<feed xmlns="http://www.w3.org/2005/Atom">
<title>Daniel123 - Latest News</title>
<link href="https://news.arcnewswire.com/rss/daniel123/latest.xml"></link>
<updated>2026-09-20T11:48:00+00:00</updated>
<id>urn:uuid:be2cffac-bf59-9942-9703-3ec91d26b6a6</id>
<entry>
<title>Pericarditis Global Clinical Trials Review, H2, 2016 - Market Trends, Regulations, and Competitive Landscape examined in new market</title>
<link href="https://news.arcnewswire.com/@daniel123/pericarditis-global-clinical-trials-review-h2-2016-market-trends-regulations-and-competitive-landscape-examined-in-new-market-qw8dekjm436n"></link>
<id>urn:uuid:29be7228-05ba-0ddf-22fa-f7b71400adbd</id>
<summary type="html"><![CDATA[GlobalData's clinical trial report, Pericarditis Global Clinical Trials Review, H2, 2016" provides an overview of Pericarditis clinical trials scenario.]]></summary>
<updated>2016-09-09T07:34:13+00:00</updated>
</entry>
<entry>
<title>Global Unstable Angina Clinical Trials Review, H2, 2016 - Investment Trends, Regulations and Company Profiles examined in new market</title>
<link href="https://news.arcnewswire.com/@daniel123/global-unstable-angina-clinical-trials-review-h2-2016-investment-trends-regulations-and-company-profiles-examined-in-new-market-4n3b5xayp8pq"></link>
<id>urn:uuid:e3d29e61-db0b-ff43-ea3a-b57c36de5921</id>
<summary type="html"><![CDATA[GlobalData's clinical trial report, Unstable Angina Global Clinical Trials Review, H2, 2016" provides an overview of Unstable Angina clinical trials scenario.]]></summary>
<updated>2016-09-09T07:32:38+00:00</updated>
</entry>
<entry>
<title>Multiple Myeloma - China Drug Market Analysis to 2023 - Size, Competitive Landscape, Key Country overview and Forecasts</title>
<link href="https://news.arcnewswire.com/@daniel123/multiple-myeloma-china-drug-market-analysis-to-2023-size-competitive-landscape-key-country-overview-and-forecasts-yd8j7kd4a3kp"></link>
<id>urn:uuid:bdce7abe-d3ad-ac4a-dc6e-2ed316ab6ab4</id>
<summary type="html"><![CDATA[The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023.]]></summary>
<updated>2016-09-09T07:31:27+00:00</updated>
</entry>
<entry>
<title>Market artifice report on Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@daniel123/market-artifice-report-on-chemotherapy-induced-neutropenia-pipeline-review-h2-2016-bw3pxy5ay3rp"></link>
<id>urn:uuid:e8052dbf-49ba-a189-9a36-46a882d317ef</id>
<summary type="html"><![CDATA[The Chemotherapy Induced Neutropenia - Pipeline Review, H2 2016 report offers a comprehensive insight on the Chemotherapy Induced Neutropenia pipeline landscape.]]></summary>
<updated>2016-09-07T05:36:06+00:00</updated>
</entry>
<entry>
<title>Market artifice report on Amyloidosis - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@daniel123/market-artifice-report-on-amyloidosis-pipeline-review-h2-2016-e63mqn6j63d4"></link>
<id>urn:uuid:82244a68-073a-16a7-9503-8ff6841c8f81</id>
<summary type="html"><![CDATA[The Amyloidosis - Pipeline Review, H2 2016 report offers a comprehensive insight on the Amyloidosis pipeline landscape.]]></summary>
<updated>2016-09-07T05:35:44+00:00</updated>
</entry>
<entry>
<title>Study on potential market: High Affinity Nerve Growth Factor Receptor  - Pipeline Review, H2 2016</title>
<link href="https://news.arcnewswire.com/@daniel123/study-on-potential-market-high-affinity-nerve-growth-factor-receptor-pipeline-review-h2-2016-pj3nynwyr8xq"></link>
<id>urn:uuid:8179eaaa-be9f-5c5c-1795-38b60a9b7cc1</id>
<summary type="html"><![CDATA[Report offers a complete overview of the pharmaceutical research and development of the pipeline products that are developed by High Affinity Nerve Growth Factor Receptor]]></summary>
<updated>2016-09-06T06:13:01+00:00</updated>
</entry>
</feed>